Supplementary Figure 1 from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Wei Wang(Capital Medical University), Ze‐Hong Miao(Nanchang University), Ying-Qing Wang(Shanghai Institute of Materia Medica), Xia‐Juan Huan, Linjiang Tong, Lanping Ma(Shanghai Institute of Materia Medica), Yi Chen(Nanchang University), Jian Ding, Jun-Mei Yi(Memorial Sloan Kettering Cancer Center), Tao Meng(Qilu Hospital of Shandong University), Jingkang Shen(Shanghai Institute of Materia Medica)
Cited by 0
Related Papers
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
|Drug Resistance Updates|2022|257
Structural characteristics and functional properties of soluble dietary fiber from defatted rice bran obtained through Trichoderma viride fermentation
|Food Hydrocolloids|2019|238
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|Signal Transduction and Targeted Therapy|2021|204
A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|bioRxiv (Cold Spring Harbor Laboratory)|2020|168
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
|Journal for ImmunoTherapy of Cancer|2020|153